RESEARCH MONOGRAPH · KDC-MN-366

Teriparatide

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

84/100

First true anabolic bone agent, mechanism is paradoxical and elegant in equal measure

Teriparatide is recombinant PTH 1-34, the N-terminal active fragment of full-length parathyroid hormone. The pharmacology is one of the prettier paradoxes in endocrinology: chronic continuous PTH elevation drives bone resorption (which is what hyperparathyroidism does), but intermittent daily injection of PTH 1-34 drives bone formation. Same hormone, opposite effect, dictated by exposure pattern.

The mechanism explanation centers on osteoblast biology. Intermittent PTH activates the PTH1 receptor on osteoblasts, triggering a transcriptional program that includes RUNX2, OSX, and downstream osteoblast differentiation and survival signals. The duration of exposure matters because chronic PTH stimulation shifts the balance toward RANKL-driven osteoclast activation, while pulsed exposure favors anabolic osteoblast activity. The Bilezikian, Kronenberg, and Bringhurst groups have been on this story for decades and the model is mechanistically coherent at this point.

The clinical evidence for osteoporosis is solid. The Neer et al fracture trial (NEJM 2001) showed roughly 65 percent reduction in vertebral fracture and around 50 percent in non-vertebral fracture after about 19 months of daily injection in postmenopausal women with severe osteoporosis. Bone mineral density gains were striking, especially at lumbar spine. The follow-on work in glucocorticoid-induced osteoporosis and male osteoporosis is similarly positive.

What's interesting from a research angle is what teriparatide demonstrated about treatment sequencing. The anabolic effect attenuates after about 18 to 24 months, which is why the clinical recommendation is to follow teriparatide with an antiresorptive (denosumab, bisphosphonate) to preserve the BMD gains. The ARMADA, VERO, and DATA trials worked out the sequencing logic.

Sourcing as a research reagent is straightforward. PTH 1-34 is a 34-residue peptide, synthesis is routine, the lyophilized peptide is stable and HPLC characterization is standard. Forteo is the proprietary formulation but research-grade PTH 1-34 is widely available.

What we dont love is the historical osteosarcoma signal from rat studies, which led to the original 2-year treatment cap and the black box. Subsequent human epidemiology hasn't borne out the carcinogenicity concern at clinical exposures and the FDA removed the cap in 2020.

Genuinely useful tool compound, both clinically and for studying PTH receptor signaling and bone anabolic mechanisms.

Evidence: 92
Mechanism: 90
Reliability: 88
Safety: 80
Sourcing: 82
Value: 70
Signal: 82
Staying power: 88

Plain-language summary Intrigue 64 / 100

Teriparatide, sold as Forteo, is the first 34 amino acids of parathyroid hormone given as a injection for osteoporosis. The pharmacology is paradoxical: continuous high PTH (as in hyperparathyroidism) causes net bone loss by stimulating osteoclast resorption, but pulsed injections drive osteoblast activation instead, building bone faster than it is broken down. This made teriparatide the first true anabolic osteoporosis drug, opposed to the bisphosphonates and other antiresorptives that just slow bone loss. Approved by the FDA in 2002, it is used for severe osteoporosis or in patients who fail antiresorptive therapy. Treatment is limited to two years over osteosarcoma concerns from animal studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Recombinant PTH 1-34 anabolic bone agent

Recombinant parathyroid hormone fragment 1-34; the first true anabolic agent for osteoporosis.

Abstract

Teriparatide (parathyroid hormone (1-34) recombinant; CAS 52232-67-4; 34-amino-acid peptide; molecular weight approximately 4117 Da) is a recombinant fragment of human parathyroid hormone (the biologically active N-terminal portion), approved by the FDA in 2002 (Forteo). Mechanism is paradoxical: chronic continuous high PTH (as in hyperparathyroidism) drives net bone resorption via osteoclast activation, but pulsatile PTH 1-34 administration drives net bone formation via direct osteoblast activation and reduced osteoblast apoptosis. The mechanism explanation involves PTH receptor-G protein signaling kinetics that favor osteoblast over osteoclast effects under intermittent stimulation. Plasma half-life is approximately 1 hour. Approved for severe osteoporosis with high fracture risk. The 2-year cumulative-dose limitation reflects an osteosarcoma signal observed in rat carcinogenicity studies (subsequently not reproduced in humans). Used as the canonical anabolic bone agent in osteoporosis research.

Mechanism of action

Recombinant PTH 1-34; intermittent administration drives osteoblast activation (anabolic effect) rather than the resorptive effect of chronic PTH excess.

Reported research dose ranges

Clinical 20 mcg subcutaneous for up to 2 years.

References

Neer RM, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001.
Vahle JL, et al. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34). Toxicol Pathol 2002.
Cosman F, et al. Treatment sequence matters: anabolic and antiresorptive therapy for osteoporosis. J Bone Miner Res 2017.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-366

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Teriparatide

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs